From GlobeNewswire: 2025-04-02 09:20:00

The Endocrine Testing Market, valued at USD 12.6 billion in 2023, is projected to reach USD 27.2 billion by 2032 with a CAGR of 8.9%. Rising endocrine disorders and technological advancements are driving market growth. The US dominates with a 33% market share, aided by advanced healthcare infrastructure and government support.

Thyroid Stimulating Hormone (TSH) tests accounted for 27% of revenue in 2023 due to high thyroid disorder prevalence. Tandem mass spectrometry (MS/MS) dominated with 25% revenue share, offering high sensitivity and specificity. Hospitals held 68% market share in 2023, with advanced testing infrastructure and Medicare coverage driving growth.

North America leads the market with a 39% share, driven by high healthcare expenditure and government support. Europe and APAC also show significant growth due to strict regulations, national screening programs, and increasing healthcare investment. The market is expected to continue expanding with increasing awareness and technological advancements. Government initiatives like India’s National Program for Prevention & Control of Diabetes are driving growth in the endocrine testing market. Major players include Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, and more. Recent developments include Quest Diagnostics’ enhanced thyroid testing panel and FDA clearance for Roche Diagnostics Elecsys cortisol assay. The market analysis & outlook report for 2024-2032 provides insights on market dynamics, competitive landscape, regional analysis, and more. For more information or customization, contact SNS Insider, a leading market research and consulting agency.



Read more at GlobeNewswire: Endocrine Testing Market to Hit USD 27.2 Billion by 2032,